LU88267I2 - - Google Patents

Info

Publication number
LU88267I2
LU88267I2 LU88267C LU88267C LU88267I2 LU 88267 I2 LU88267 I2 LU 88267I2 LU 88267 C LU88267 C LU 88267C LU 88267 C LU88267 C LU 88267C LU 88267 I2 LU88267 I2 LU 88267I2
Authority
LU
Luxembourg
Application number
LU88267C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT22383/84A external-priority patent/IT1175620B/it
Priority claimed from IT21460/85A external-priority patent/IT1187678B/it
Application filed filed Critical
Publication of LU88267I2 publication Critical patent/LU88267I2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03BMANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2205/00Fibre drawing or extruding details
    • C03B2205/44Monotoring or regulating the preform feed rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU88267C 1984-08-22 1985-08-21 LU88267I2 (pm)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22383/84A IT1175620B (it) 1984-08-22 1984-08-22 Derivati piridinici
IT21460/85A IT1187678B (it) 1985-07-05 1985-07-05 Procedimento di preparazione di derivati eterociclici

Publications (1)

Publication Number Publication Date
LU88267I2 true LU88267I2 (pm) 1994-02-03

Family

ID=26327905

Family Applications (2)

Application Number Title Priority Date Filing Date
LU88267C LU88267I2 (pm) 1984-08-22 1985-08-21
LU86047A LU86047A1 (fr) 1984-08-22 1985-08-21 Derives heterocycliques

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU86047A LU86047A1 (fr) 1984-08-22 1985-08-21 Derives heterocycliques

Country Status (33)

Country Link
US (2) US4801599A (pm)
JP (2) JPS6193162A (pm)
KR (1) KR920004482B1 (pm)
AT (1) AT394042B (pm)
AU (1) AU578724B2 (pm)
BE (1) BE903103A (pm)
BG (1) BG60409B2 (pm)
CA (1) CA1268180A (pm)
CH (1) CH666684A5 (pm)
CS (1) CS403091A3 (pm)
CY (1) CY1494A (pm)
DE (1) DE3529997C2 (pm)
DK (1) DK165949C (pm)
ES (5) ES8703839A1 (pm)
FI (1) FI81568C (pm)
FR (1) FR2569402B1 (pm)
GB (1) GB2164336B (pm)
GR (1) GR852016B (pm)
HK (1) HK52990A (pm)
HU (1) HU196754B (pm)
IE (1) IE58486B1 (pm)
LU (2) LU88267I2 (pm)
MX (1) MX159974A (pm)
NL (2) NL193065C (pm)
NO (2) NO167142C (pm)
NZ (1) NZ212895A (pm)
PH (1) PH22014A (pm)
PT (1) PT81000B (pm)
SA (1) SA91120277B1 (pm)
SE (1) SE459920B (pm)
SG (1) SG40889G (pm)
SK (1) SK278327B6 (pm)
ZW (1) ZW13185A1 (pm)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3675747D1 (de) * 1985-08-21 1991-01-03 Glaxo Spa 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.
ES2001104A6 (es) * 1985-08-21 1988-04-16 Glaxo Spa Un procedimiento para la preparacion de nuevos derivados sustituidos del acido 1,4-dihidro-3,5-piridindicarboxilico.
IT1204461B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204460B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204462B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1233370B (it) * 1988-11-21 1992-03-27 Glaxo Spa Procedimento di preparazione di derivati diidropipiridinici utili nel trattamento di disturbi cardiovascolari
DE69030982T2 (de) 1989-04-27 1997-11-13 Canon Kk Optisches Aufzeichnungsmedium und Verfahren zu seiner Herstellung
US5196529A (en) * 1990-10-09 1993-03-23 Merck & Co., Inc. 2-phenanthrenyl carbapenem intermediates
US5177202A (en) * 1990-10-09 1993-01-05 Merck & Co., Inc. 2-phenanthrenyl-carbapenems
US5132421A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5132422A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5144028A (en) * 1990-10-09 1992-09-01 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5356889A (en) * 1990-08-01 1994-10-18 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
IT1244728B (it) * 1991-02-13 1994-08-08 Glaxo Spa Impiego medicamentoso di derivati diidropiridinici
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
AP2005003232A0 (en) 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
JP2008507585A (ja) * 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
EP1868577A4 (en) 2005-04-15 2009-12-09 Reddys Lab Inc Dr Lacidipine PARTICLE
US20070043088A1 (en) * 2005-08-16 2007-02-22 Eswaraiah Sajja Process for preparing lacidipine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
EP2049102A4 (en) * 2006-07-14 2010-12-22 Ranbaxy Lab Ltd POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
US20080089947A1 (en) * 2006-08-18 2008-04-17 Knox Clayton D Calcium Influx Inhibitors in the Treatment of Ischemia
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
ITMI20131485A1 (it) 2012-09-10 2014-03-11 Rivopharm Sa Composizione farmaceutica comprendente lacipidina e processo di preparazione
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455945A (en) * 1967-06-07 1969-07-15 Smithkline Corp 4-(carboxy (and carbo-lower alkoxy)phenyl)-1,4-dihydropyridines
DE2228363A1 (de) * 1972-06-10 1974-01-03 Bayer Ag 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1409865A (en) * 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
DE3018259A1 (de) * 1980-05-13 1981-11-19 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine mit unterschiedlichen substituenten in 2- und 6-position, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
HU196754B (en) 1989-01-30
ES552051A0 (es) 1987-09-01
DK378085D0 (da) 1985-08-20
ATA245485A (de) 1991-07-15
JPH0550506B2 (pm) 1993-07-29
PH22014A (en) 1988-05-02
HUT40625A (en) 1987-01-28
ES552050A0 (es) 1987-09-01
ES8707931A1 (es) 1987-09-01
ES8703839A1 (es) 1987-03-01
FR2569402A1 (fr) 1986-02-28
NO167142C (no) 1991-10-09
FI81568C (fi) 1990-11-12
AU578724B2 (en) 1988-11-03
NZ212895A (en) 1988-07-28
SE459920B (sv) 1989-08-21
SG40889G (en) 1989-12-22
NL193065C (nl) 1998-09-08
IE852054L (en) 1986-02-22
IE58486B1 (en) 1993-09-22
FI853206L (fi) 1986-02-23
JPS6479152A (en) 1989-03-24
ES552049A0 (es) 1988-07-01
CY1494A (en) 1990-02-16
KR920004482B1 (ko) 1992-06-05
MX159974A (es) 1989-10-17
FI81568B (fi) 1990-07-31
NL980037I2 (nl) 1999-03-01
GB2164336B (en) 1988-06-08
DE3529997C2 (de) 1996-01-18
ES546324A0 (es) 1987-03-01
JPH0686430B2 (ja) 1994-11-02
GB8520924D0 (en) 1985-09-25
LU86047A1 (fr) 1986-02-28
KR870002073A (ko) 1987-03-28
BE903103A (fr) 1986-02-24
DE3529997A1 (de) 1986-03-06
GR852016B (pm) 1985-12-19
US5011848A (en) 1991-04-30
AU4657685A (en) 1986-02-27
NO853293L (no) 1986-02-24
CA1268180A (en) 1990-04-24
NL193065B (nl) 1998-05-06
HK52990A (en) 1990-07-20
NL8502296A (nl) 1986-03-17
US4801599A (en) 1989-01-31
PT81000A (en) 1985-09-01
SE8503888L (sv) 1986-02-23
ES8707932A1 (es) 1987-09-01
FI853206A0 (fi) 1985-08-21
NL980037I1 (nl) 1999-02-01
DK378085A (da) 1986-02-23
NO1999007I1 (no) 1999-04-23
ES8707930A1 (es) 1987-09-01
CS403091A3 (en) 1992-06-17
DK165949C (da) 1993-07-05
NO167142B (no) 1991-07-01
SA91120277B1 (ar) 2006-05-15
GB2164336A (en) 1986-03-19
DK165949B (da) 1993-02-15
PT81000B (pt) 1988-03-03
SE8503888D0 (sv) 1985-08-20
BG60409B2 (bg) 1995-02-28
CH666684A5 (de) 1988-08-15
AT394042B (de) 1992-01-27
ES8802497A1 (es) 1988-07-01
SK278327B6 (en) 1996-11-06
JPS6193162A (ja) 1986-05-12
FR2569402B1 (fr) 1989-09-22
ES552048A0 (es) 1987-09-01
ZW13185A1 (en) 1986-03-19

Similar Documents

Publication Publication Date Title
GR852016B (pm)
GR851827B (pm)
GR851835B (pm)
GR851538B (pm)
GR852099B (pm)
DE3565651D1 (pm)
GR850347B (pm)
GR852799B (pm)
IN159528B (pm)
GR74382B (pm)
GR74224B (pm)
GR73963B (pm)
GR851353B (pm)
GR76557B (pm)
GR76637B (pm)
BG45280A1 (pm)
BG45181A1 (pm)
BG44933A1 (pm)
BG44935A1 (pm)
BG45025A1 (pm)
CA1252095C (pm)
BG45334A1 (pm)
BG45317A1 (pm)
BG45296A1 (pm)
BG45163A1 (pm)